维生素D补充与癌症预防:D2d癌症结局辅助研究
D2dCA是D2d研究的辅助研究,在美国22家学术医学中心纳入2385例有糖尿病前期和超重/肥胖、近5年无癌症的参与者,随机接受维生素D3 4000 IU/日或安慰剂。中位随访2.9年,癌症发病风险HR为1.07(95% CI 0.70, 1.62),结直肠息肉HR为0.83(95% CI 0.64, 1.07),均无显著影响。
要点
- 在糖尿病前期和超重/肥胖人群中,维生素D补充未显著降低癌症发病风险。
- 维生素D对结直肠腺瘤性息肉的HR为0.83(95% CI 0.64, 1.07),无统计学显著性。
- 该人群未按维生素D缺乏筛选,基线25-羟基维生素D平均为28 ng/mL。
核心结论
- 在有糖尿病前期和超重/肥胖、未按维生素D不足筛选的人群中,维生素D补充对癌症发病或结直肠息肉风险无显著影响。
研究设计与样本
- D2dCA为D2d研究的辅助研究,在美国22家学术医学中心开展。
- 纳入2385例有糖尿病前期和超重/肥胖、近5年无癌症的参与者,随机接受维生素D3 4000 IU/日或安慰剂。
- 每年4次研究访视,通过问卷识别癌症和癌前病变事件,并收集临床数据加以判定。
- 采用Cox比例风险模型比较两组癌症和癌前病变发病的风险比(HR)。
主要发现
- 中位随访2.9年,2385例参与者(平均年龄60岁,25-羟基维生素D 28 ng/mL)中共发生89例癌症。
- 维生素D组相比安慰剂组,癌症发病的HR为1.07(95% CI 0.70, 1.62)。
- 241例发生癌前病变的参与者中,239例为结直肠腺瘤性息肉。
- 维生素D组相比安慰剂组,结直肠息肉的HR为0.83(95% CI 0.64, 1.07)。
临床怎么用
- 对于有糖尿病前期和超重/肥胖、未筛选维生素D不足的人群,不宜以预防癌症为目的常规补充维生素D3 4000 IU/日。
- 对结直肠息肉风险的影响未达统计学显著,临床决策应结合个体情况。
局限性
- 中位随访仅2.9年,事件数有限(癌症89例)。
- 人群未按维生素D不足筛选,基线25-羟基维生素D平均28 ng/mL,结果不能外推至维生素D缺乏人群。
- 癌前病变事件绝大多数为结直肠腺瘤性息肉,其他癌前病变信息有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Observational studies suggest that low vitamin D status may be a risk factor for cancer. OBJECTIVE: In a population with prediabetes and overweight/obesity that is at higher risk of cancer than the general population, we sought to determine if vitamin D supplementation lowers the risk of cancer and precancers. METHODS: The Vitamin D and type 2 diabetes (D2d) cancer outcomes study (D2dCA) is an ancillary study to the D2d study, which was conducted at 22 academic medical centers in the United States. Participants had prediabetes and overweight/obesity and were free of cancer for the previous 5 years. Participants were randomized to receive vitamin D3 4000 IU daily or placebo. At scheduled study visits (4 times/year), cancer and precancer events were identified by questionnaires. Clinical data were collected and adjudicated for all reported events. Cox proportional hazard models compared the hazard ratio (HR) of incident cancers and precancers between groups. RESULTS: Over a median follow-up period of 2.9 years, among 2385 participants (mean age 60 years and 25-hydroxyvitamin D 28 ng/mL), there were 89 cases of cancer. The HR of incident cancer for vitamin D vs placebo was 1.07 (95% CI 0.70, 1.62). Of 241 participants with incident precancers, 239 had colorectal adenomatous polyps. The HR for colorectal polyps for vitamin D vs placebo was 0.83 (95% CI 0.64, 1.07). CONCLUSION: In the D2d population of participants with prediabetes and overweight/obesity, not selected for vitamin D insufficiency, vitamin D supplementation did not have a significant effect on risk of incident cancer or colorectal polyps.
引用
- Chatterjee R, Fuss P, Vickery EM, et al. Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study. J Clin Endocrinol Metab. 2021. PMID: 33693713. doi:10.1210/clinem/dgab153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。